PRKDC and breast cancer: Currently, PARP1 inhibitors become promising drugs in breast cancer treatment, which can delay the parylation of DNA repair factors, such as Ku70, DNA‐PKcs, BARD1 etc.38, 39 Thus, inhibition of PARP1 would affect the interactions between DNA repair factors and the DNA breaks to impair the DNA damage response.